Excited to share our review (BCL-2i in WM and MZL). Thanks to all the authors, the DFCI ⁦Dana-Farber⁩, and especially Prof. J. Castillo. ⁦British Journal of Haematology⁩ ⁦Andrew M. Evens, DO, MBA, MSc⁩ #lymphoma #lylsm #lylnh #lylnhmz onlinelibrary.wiley.com/doi/epdf/10.11…

Putting these data together is a great achievement. But more is needed. Stakeholders, directors, mentors, big bosses : reducing burnout (ie saving lives) is in your hand ! Please read and share with colleagues. YoungEHA

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Review Cell Reports 🇨🇳 Metabolic regulation of immunity in the tumor microenvironment cell.com/cell-reports/f…

Very nice editorial on our recent Blood paper! ashpublications.org/blood/article/…

Ibrutinib shows favorable efficacy across all lines of treatment; however, intolerance and discontinuation are common. Read in Blood Global Hematology: ow.ly/1p5450Xh3UK

Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry ⁦Blood Advances⁩ ‘failure’ after 3 months from CAR T infusion Bispecific antibodies improve PFS after CAR T relapse cf other therapies ashpublications.org/bloodadvances/…

Who Is Eligible for CAR T-Cell Therapy? Expert Perspectives on Overcoming Referral Barriers Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia buff.ly/4Uy1kFv

New publication📝Phase II results, published in Blood, show zanubrutinib + rituximab + lenalidomide was associated with a CR rate of 65% in patients aged ≥75 years with de novo DLBCL. Learn more: LymphomaHub.com #lymphoma #lymsm #MedNews #MedEd

Celebrating 35 years of academic excellence! The IFM has led groundbreaking trials shaping the modern era of high-dose therapy in myeloma. Proud to see this legacy highlighted in ⁦Blood Cancer Journal⁩ , showcasing how IFM research has set global standards for myeloma care.

Designing a strong bridge to CAR-T cells with bispecifics #mmsm #bmtsm Mattia D’Agostino ashpublications.org/blood/article/…

#CLL and the biggest of all: CLL17 out - very impressive study: I vs IV, vs Obi-Ven. Non-inferiority of fixed duration regimen vs continuous ibrutinib. meetings-api.hematology.org/api/abstract/v… Feels like the field is ready for randomized MRD guided vs Fixed duration!

Sonrotoclax monotherapy in 125 R/R #MCL pts Look out for this being updated with longer fup at the #ASH25 meeting submit.hematology.org/program/presen…

Many congratulations to the GCLLSG for the first read out of #CLL17 No PFS diff between I+V vs I vs VO. Shorter fup but v different to FLAIR results showing a marked PFS adv for MRD-directed I+V vs I. #ASH25 submit.hematology.org/program/presen…

Outstanding primary analysis (pre-planned IA) of EPCORE FL-1 Remarkable that it isn't in plenary at #ASH25 #FL E+R2 N=243 vs R2 N=245 POD24 in 43% vs 36% prior lines 1 (range, 1–7) vs 1 (range, 1–6) PFS HR 0.21; 95% CI: 0.13-0.33 p<.0001 Trade off: inc. infections, low CRS risk.

MarieJosé Kersten et al. Impressive early data from ATALANTA-1 MCL cohort #ASH25 #MCL submit.hematology.org/program/presen…

A review of interactions between the gut microbiome, brain and sleep disorders genomicpress.kglmeridian.com/view/journals/…

📢 𝗪𝗲 𝗮𝗿𝗲 𝗟𝗜𝗩𝗘 𝗨𝗽𝗱𝗮𝘁𝗲𝘀 𝗶𝗻 𝗖𝗔𝗥 𝗧 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗼𝗿 𝗟𝗮𝗿𝗴𝗲 𝗕 𝗖𝗲𝗹𝗹 𝗟𝘆𝗺𝗽𝗵𝗼𝗺𝗮 💻𝘙𝘦𝘨𝘪𝘴𝘵𝘦𝘳 𝘧𝘰𝘳 𝘍𝘙𝘌𝘌 us06web.zoom.us/webinar/regist… Andrew Jallouk Mohamad Mohty Bipin Savani

Well worth a read! link.springer.com/article/10.100…